Vect-Horus Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
40
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
Vect-Horus General Information
Description
Developer of a targeted drug delivery system intended to enhance the transport of biotherapeutics across biological barriers. The company's system is based on the specific design and optimization of molecular vectors that once conjugated to a payload delivered to target cells in the body, enabling healthcare providers to improve therapeutic or diagnostic benefits while minimizing both dose levels and off-target effects of newly developed molecules.
Contact Information
Website
www.vect-horus.comCorporate Office
- Faculty of Timone
- 27 Boulevard Jean Moulin, 1st floor Green Wing
- 13005 Marseille
- France
Corporate Office
- Faculty of Timone
- 27 Boulevard Jean Moulin, 1st floor Green Wing
- 13005 Marseille
- France
Vect-Horus Timeline
Vect-Horus Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | 0000 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 18-Apr-2023 | 00.000 | 0000 | 000.00 | Completed | Generating Revenue |
| 10. Grant | 01-Feb-2022 | 000 | 000.00 | Completed | Generating Revenue | |
| 9. Later Stage VC (Series D) | 01-Dec-2020 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 8. Later Stage VC | 07-Jun-2018 | 00.000 | 000.00 | 0000 | Completed | Generating Revenue |
| 7. Later Stage VC | 21-Mar-2017 | 00.000 | 000.00 | 0000 | Completed | Generating Revenue |
| 6. Accelerator/Incubator | 00.000 | Completed | Generating Revenue | |||
| 5. Angel (individual) | 00.000 | 00.000 | Completed | Generating Revenue | ||
| 4. Later Stage VC | 15-Dec-2014 | $1.86M | $1.86M | Completed | Generating Revenue | |
| 3. Grant | $5.57M | Completed | Startup |
Vect-Horus Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.00 | ||
| Ordinary | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Vect-Horus Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vect-Horus Patents
Vect-Horus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020206593-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | 00000000000 | |
| US-20220090050-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | 00000000000 | |
| CA-3124790-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | 00000000000 | |
| JP-2022518392-A | Transferrin receptor binding molecule, its conjugate, and its use | Pending | 09-Jan-2019 | 00000000000 | 0 |
| EP-3908608-A1 | Transferrin receptor-binding molecules, conjugates thereof and their uses | Pending | 09-Jan-2019 | C12N15/1037 |
Vect-Horus Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Alexandre Tokay | Co-Founder, Chief Executive Officer, President & Chairman | |
| Jean Pean Ph.D | Chief Scientific Officer | |
| Michel Khrestchatisky Ph.D | Co-Founder & Scientific Counsel | |
| Jamal Temsamani Ph.D | Chief Business Officer, Director of Drug Development and Corporate & Member of the Management Committee |
Vect-Horus Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Vect-Horus Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| European Union | Government | 000 0000 | 000000 0 | |
| Bpifrance | Sovereign Wealth Fund | Minority | 000 0000 | 000000 0 |
| CAAP Creation | Venture Capital | Minority | 000 0000 | 000000 0 |
| Financiere Tuileries Development | Corporation | Minority | 000 0000 | 000000 0 |
| Alizee Investment | Corporation | Minority | 000 0000 | 000000 0 |
Vect-Horus FAQs
-
When was Vect-Horus founded?
Vect-Horus was founded in 2005.
-
Who is the founder of Vect-Horus?
Alexandre Tokay and Michel Khrestchatisky Ph.D are the founders of Vect-Horus.
-
Who is the CEO of Vect-Horus?
Alexandre Tokay is the CEO of Vect-Horus.
-
Where is Vect-Horus headquartered?
Vect-Horus is headquartered in Marseille, France.
-
What is the size of Vect-Horus?
Vect-Horus has 40 total employees.
-
What industry is Vect-Horus in?
Vect-Horus’s primary industry is Drug Delivery.
-
Is Vect-Horus a private or public company?
Vect-Horus is a Private company.
-
What is Vect-Horus’s current revenue?
The current revenue for Vect-Horus is 000000.
-
How much funding has Vect-Horus raised over time?
Vect-Horus has raised $35M.
-
Who are Vect-Horus’s investors?
European Union, Bpifrance, CAAP Creation, Financiere Tuileries Development, and Alizee Investment are 5 of 6 investors who have invested in Vect-Horus.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
